###  [:house:返回首頁](https://github.com/ourhimalayas/txt)
---

## 【司法部】生產瑞德西韋的吉利德公司因非法支付回扣給聯邦醫療保險計劃的患者被指控
`2020-09-25 17:18 Isaiah4031` [轉載自GNews](https://gnews.org/zh-hant/382745/)

![]()![](https://s3.amazonaws.com/gnews-media-offload/wp-content/uploads/2020/09/25170905/DOJ_20200923_Gilead-photo169.png)圖片來源：[freestocks](https://unsplash.com/@freestocks?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText) on [Unsplash](https://unsplash.com/s/photos/pharmaceutical-company?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText)
新聞簡述：司法部指控生產瑞德西韋的吉利德公司（Gilead）因向患者支付一種高血壓藥物的回扣的行為而需支付9,700萬美元以解決其虛假索償的違法行為。制藥公司的此種違法回扣行為造成高昂的藥物價格最終由納稅人承擔。川普總統早前通過多項行政令用以阻止力量強大的制藥廠多年來對美國醫藥市場的控制，來造福普通美國納稅人和病人。司法部對此事的實際行動表明政府對打擊醫療欺詐的重視和決心。
![]()![](https://s3.amazonaws.com/gnews-media-offload/wp-content/uploads/2020/09/25170848/DOJ_20200923_Gilead-figure1.png)
Department of Justice

Office of Public Affairs

司法部公共事務辦公室

FOR IMMEDIATE RELEASE

Wednesday, September 23, 2020

2020年9月23日即時發佈

**Gilead Agrees To Pay $97 Million To Resolve Alleged False Claims Act Liability For Paying Kickbacks**

**吉利德因支付回扣的行為而同意支付9,700萬美元以解決虛假索償行為**

Pharmaceutical company Gilead Sciences, Inc. (Gilead), based in Foster City, California, has agreed to pay $97 million to resolve claims that it violated the False Claims Act by illegally using a foundation as a conduit to pay the copays of thousands of Medicare patients taking Gilead’s pulmonary arterial hypertension drug, Letairis, the Justice Department announced today.

司法部今天宣佈：總部位於加利福尼亞州福斯特城的制藥公司吉利德科學公司（Gilead）已同意支付9,700萬美元，以解決其違反《虛假索賠法》的指控，即非法利用基金會作為途徑來支付，服用吉利德肺動脈高壓藥物萊泰利斯的患者的數千份Medicare醫療保險自付額的部分。

“This settlement demonstrates the government’s commitment to hold accountable companies that pay illegal kickbacks, whether directly or through a third party,” said Acting Assistant Attorney General Jeffrey Bossert Clark of the Department of Justice’s Civil Division.  “We will not allow permit pharmaceutical manufacturers to set unaffordable drug prices while circumventing important cost-control mechanisms within the Medicare program.”

司法部民事司代理司法助理部長傑弗里·博塞特·克拉克說：「這項和解表明，政府承諾對直接或通過第三方支付非法回扣的責任公司負責。」 「我們將不允許許可的藥品製造商設定難以承受的藥品價格，同時繞開Medicare計劃內的重要成本控制機制。」

“Like its competitors, Actelion and United Therapeutics, Gilead used data from CVC that it knew it should not have, and effectively set up a proprietary fund within CVC to cover the co-pays of just its own drug,” said U.S. Attorney Andrew E. Lelling for the District of Massachusetts.  “Such conduct not only violates the anti-kickback statute, it also undermines the Medicare program’s co-pay structure, which Congress created as a safeguard against inflated drug prices. During the period covered by today’s settlement, Gilead raised the price of Letairis by over seven times the rate of overall inflation in the United States.”

為馬薩諸塞州地區提供服務的美國律師Andrew E. Lelling說「與競爭對手Actelion和United Therapeutics一樣，吉利德使用了他們本不該使用的CVC數據，並有效地在CVC內設立了一個專有基金來支付其自己藥物的共同費用」， 「這種行為不僅違反了反回扣法，而且破壞了聯邦醫療保險計劃 Medicare 的共付結構，國會為防止藥品價格飛漲而建立了這種結構。在今天的和解協議涵蓋的期間內，吉利德將 Letairis 的藥品價格提高超過了美國總體通脹率的七倍以上。」

“When pharmaceutical companies deceitfully employ the charitable donation process as an instrument to subsidize copays for their own drugs, it subverts a critical safeguard against the excessive inflation of drug costs,” said Phillip M. Coyne, Special Agent in Charge, Office of the Inspector General of the Department of Health and Human Service’s Boston Regional Office.  “Manipulation of this process threatens the integrity of our federal healthcare system, disregarding the American taxpayer who ultimately bears the cost.  As such, we remain vigilantly focused on confronting this type of conduct and will continue our aggressive enforcement in this area.”

檢查員辦公室特別負責人、衛生與公共服務部波士頓地區辦公室的 Phillip M. Coyne說：「當制藥公司欺騙性地將慈善捐贈程序作為一種手段來補貼自己的藥品自付額時，它就破壞了防止藥品成本過度膨脹的關鍵保障。」 並說： 「對這一程序的操縱威脅到我們聯邦醫療體系的廉正，無視最終承擔費用的美國納稅人。因此，我們將繼續保持警惕，著力應對這種行為，並將繼續在這一領域積極執法。」

“Health care fraud costs our country tens of billions of dollars each year because of unscrupulous schemes like the one Gilead orchestrated that dangled kickbacks disguised as copay assistance in front of Medicare patients,”  said Joseph R. Bonavolonta, Special Agent in Charge of the Federal Bureau of Investigations, Boston Division.  “Today’s $97 million settlement ensures Gilead pays for defrauding a government insurance program and reaffirms the FBI’s resolve to pursue investigations and exhaust all efforts to uncover these schemes.”

波士頓局調查局聯邦主管特工約瑟夫·R·博納沃隆塔說：「醫療欺詐導致我們國家每年損失數百億美元，例如吉利德精心策劃的一項計劃，這些計劃偽裝成在醫療保險患者面前作為共付額援助的回扣。」 「今天的9,700萬美元和解協議確保了吉利德為其欺詐政府保險計劃而付出了代價，並重申了聯邦調查局決心進行調查並竭盡全力發現此種陰謀詭計。」

When a Medicare beneficiary obtains a prescription drug covered by Medicare, the beneficiary may be required to make a partial payment, which may take the form of a copayment, coinsurance, or a deductible (collectively “copays”).  Congress included copay requirements in the Medicare program, in part, to serve as a check on health care costs, including the prices that pharmaceutical manufacturers can demand for their drugs.

當 Medicare 受益人獲得 Medicare 承保的處方藥時，可能會要求受益人支付部分付款，該付款可以採取共付額、共同保險或免賠額的形式（統稱為「共付額」）。國會在醫療保險計劃中包括了共付額要求，在某種程度上是對醫療保健費用的一種核查，這個費用就包括醫藥製造商的藥品要價。

Under the Anti-Kickback Statute, a pharmaceutical company is prohibited from offering or paying, directly or indirectly, any remuneration — which includes money or any other thing of value — to induce Medicare patients to purchase the company’s drugs.  This prohibition extends to the payment of patients’ copay obligations.

根據《反回扣法》，禁止制藥公司直接或間接提供或支付任何報酬（包括金錢或任何其它有價物）以誘使 Medicare 患者購買公司的藥物。該禁令涵蓋對患者共付額的支付義務的管轄。

Gilead sells Letairis, which is approved for treatment of pulmonary arterial hypertension.  The government alleged that Gilead used a foundation, which claims 501(c)(3) status for tax purposes, as a conduit to pay the copay obligations of thousands of Medicare patients taking Letairis and to induce those patients to purchase Letairis, because it knew that the prices Gilead set for Letairis could otherwise pose a barrier to those purchases.  From 2007 through 2010, Gilead made payments to the foundation, which, in turn, used those funds to pay copays of patients prescribed Letairis.  The government alleged that Gilead routinely obtained data from the foundation detailing how much the foundation had spent for patients on Letairis; it then used this information to decide how much to pay to the foundation and to confirm that its payments were sufficient to cover the copays of only patients taking Letairis.  The government also alleged that, to generate revenue from Medicare and induce purchases of Letairis, Gilead referred Medicare patients to the foundation, which resulted in claims to Medicare to cover the cost of Letairis.

吉利德出售的 Letairis，該產品是被批准的用於治療肺動脈高壓的藥物。政府聲稱吉利德利用一家基金會（該基金會出於稅收目的有 501(c)(3) 身份）作為支付數千名服用Letairis的聯邦醫療保險Medicare患者的共付額義務，並誘使這些患者購買 Letairis，因為它知道吉利德為 Letairis 設定的價格可能會對購買構成障礙。從2007年到2010年，吉利德向基金會付款，該基金會又用這些資金來支付使用 Letairis 的患者的自付費用部分。政府聲稱，吉利德定期從基金會獲得數據，詳細說明基金會在 Letairis 上為患者花了多少錢。然後，它使用此信息來決定向基金會支付多少費用，並確認其付款足以支付僅服用Letairis的患者的共付額。政府還聲稱，為了從 Medicare 產生收入並誘使購買 Letairis，吉利德將 Medicare 患者轉給了基金會，這導致 Medicare 被要求支付Letairis 的費用。

The government’s resolution of this matter illustrates the government’s emphasis on combating healthcare fraud.  One of the most powerful tools in this effort is the False Claims Act.  Tips and complaints from all sources about potential fraud, waste, abuse, and mismanagement, can be reported to the Department of Health and Human Services at 800-HHS-TIPS (800-447-8477).

政府對此事的解決方案表明瞭政府對打擊醫療欺詐的重視。這項工作中最強大的工具之一是《虛假索償法》。可以通過800-HHS-TIPS（800-447-8477）向衛生和公共服務部報告有關所有潛在欺詐、浪費、濫用和管理不當的提示和投訴。

The investigation was conducted by the Civil Division’s Commercial Litigation Branch and the U.S. Attorney’s Office for the District of Massachusetts, in conjunction with the Department of Health and Human Services, Office of Inspector General and the Federal Bureau of Investigation.

這項調查是由民事訴訟部門的商業訴訟處和美國馬薩諸塞州地區檢察官辦公室，與衛生和公共服務部，監察長辦公室和聯邦調查局共同進行的。

The claims resolved by the settlement are allegations only; there has been no determination of liability.

和解解決的索賠僅是指控； 尚未確定責任。

[閱讀司法部原文](https://www.justice.gov/opa/pr/gilead-agrees-pay-97-million-resolve-alleged-false-claims-act-liability-paying-kickbacks)

翻譯報道：【Isaiah4031】

戰友之家玫瑰園小隊出品

相關新聞：

[生產瑞德西韋的吉利德公司股價已跌回疫情前，是否離放開使用羥氯喹不遠了？](https://gnews.org/zh-hans/334677/)

[川普總統在簽署降低藥品價格的行政命令時的講話(2020.7.24)](https://gnews.org/zh-hans/278064/)

0
